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Abstract  
 
Background: Recent evidence indicates the possible involvement of adenosine and the purinergic system in the 
pathophysiology of bipolar disorder (BD). The aim of this study is to compare serum uric acid (UA) levels in a large 
group of BD patients (in mania, depression and euthymia) versus a control group of patients with different psychiatric 
disorders.  
Methods: 150 BD (SCID-I; DSM-IV) patients were compared to 150 age- and gender-matched subjects with MDD, 
OCD, or Schizophrenia. Mean serum UA values were compared with the ANOVA, with Bonferroni’s post hoc tests.  
Results: Mean serum UA levels (5.06±1.45 vs. 4.17±1.05 mg/dL) and rates of hyperuricaemia (30.7 vs. 6.7%) were 
significantly higher in the bipolar than in the control group. No differences were detected between bipolars in different 
phases of illness, with all three groups (manic, depressive and euthymic bipolars) showing significantly higher UA 
levels as compared to controls. No correlations were found between UA levels and YMRS or HAM-D scores. Mean UA 
levels were also higher in bipolars never exposed to mood stabilizers vs. controls (5.08±1.43 vs. 4.17±1.05 mg/dL), 
with no differences compared to other bipolars. 
Limitations: our study suffers from the lack of a healthy comparison group; moreover, longitudinal data are missing. 
Conclusions: our study provides further evidence of a purinergic dysfunction associated with BD, in all phases of the 
illness. It is possible that increased UA levels are a trait marker of higher vulnerability to bipolar disorder, and are even 
more increased during mania (mostly in the first manic episode of drug-naïve patients). 
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Introduction 
 
Bipolar Disorders (BD) types I and II affect about 2% of the world’s population, with subthreshold forms of 
the disorder affecting another 2% (Merikangas et al., 2007; Merikangas et al., 2011). Despite a substantial expansion of 
research into bipolar disorder and potential treatments during the past 2 decades, true advances have been few (Geddes 
and Miklowitz, 2013). Little is known, in fact, concerning the etiology and underlying pathophysiology of bipolar 
disorder, in particular about the various manifestations of the disorder (depression and mania).  
Some recent evidence indicates the possible involvement of adenosine and the purinergic system in the 
pathophysiology of bipolar disorder. Adenosine, a purine nucleoside, appears to modulate both dopamine and glutamine 
and has gained attention in the underlying pathophysiology of the human central nervous system (Boison, 2008). 
Adenosine has an anticonvulsant and antikindling activity and modulates second messenger systems, neurotransmitters, 
energy metabolism and different behaviors, such as sleep, motor activity, cognition, memory, aggressive behavior and 
social interaction (Machado-Vieira et al., 2002). Adenosine agonists have shown sedative, anticonvulsant, anti-
aggressive, and antipsychotic properties, whereas its antagonists such as caffeine increase irritability, anxiety, and 
insomnia (Lara et al., 2006; Machado-Vieira, 2012). It has been hypothesized that a reduced adenosinergic activity, 
mostly at A1 receptors (with an increase in uric acid levels), is associated with the complex network of changes on 
neurotransmitters pathways related to manic behavior (Machado-Vieira et al., 2002). 
Evidences suggesting a purinergic system dysfunction in the pathophysiology of bipolar disorder are briefly 
summarized in the following paragraphs. Randomized, placebo-controlled studies found that the purinergic modulator 
allopurinol, a xanthine oxidase inhibitor used for the treatment of gout and hyperuricemia, is effective in treating acute 
mania when used adjunctively with lithium (Machado-Vieira et al., 2008), lithium and haloperidol (Akhondzadeh et al., 
2006), and sodium valproate (Jahangard et al., 2014). A recent large, well-powered, placebo-controlled study, however, 
did not find allopurinol addition to mood stabilizers (other than lithium) and/or antipsychotic (taken for a period of 
between three days and two weeks) more effective than placebo in manic patients (Weiser et al., 2014). A possible 
explanation of this discrepancy is that allopurinol might have a different effect in combination with different mood 
stabilizers. Another possible explanation for the negative results of this trial is the possibility that the use of effective 
antipsychotic and mood stabilizing treatment (although the Authors do not report the average number of adjunctive 
treatments) may have caused a ceiling effect, masking the potential benefits of allopurinol. Notwithstanding this 
negative trial, the hypothesis that allopurinol, by increasing adenosine levels in the brain, might exert an antimanic 
effect at least in some patients with bipolar mania remains interesting and results from controlled studies at least in part 
support purinergic system dysfunctions in the pathophysiology of mania (Hirota and Kishi, 2013). Lithium also has a 
potential effect in lowering uric acid levels: historically, in the 19th century, it was used to dissolve uric acid crystals in 
urine obtained from patients with gout before the first use made by Cade to treat mania in chronically hospitalized 
patients (Oruch et al., 2014). Given the specific effect of lithium on uric acid levels, it is also possible that it potentiates 
allopurinol (and viceversa), while the effect of other mood stabilizers on uric acid levels remains controversial. 
Uric acid levels were found, moreover, significantly increased in patients with bipolar disorder. Uric acid is an 
important nitrogenous end product of purinergic metabolism (ATP and adenosine). A first study found that plasma uric 
acid levels are higher during the manic phase of bipolar disorder but not during the depressive or euthymic phase (De 
Berardis et al., 2008); moreover, uric acid levels correlated with YMRS scores, suggesting a role in the pathophysiology 
of mania. A second study confirmed the increase in uric acid levels in drug-naive BD subjects during their first manic 
episode, although a correlation with YMRS scores was not found (Salvadore et al., 2010). A possible explanation of this 
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finding is the small sample size (20 patients versus 24 controls), which might have reduced statistical power. These 
findings suggest, however, that increased uric acid may be a specific state marker of mania rather than a trait (Machado-
Vieira, 2012).  
Preliminary evidence suggests, moreover, an increased occurrence of gout in patients with bipolar disorder 
(Chung et al., 2010). Increased levels of uric acid are the key biomarker in the diagnosis of gout. A nationwide 
population-based survey investigated the risk of developing gout among patients with/without bipolar disorder during a 
six-year follow-up period: the hazard of developing gout was 1.19 greater for bipolar patients than for the comparison 
cohort (16.4% vs. 13.6%)(Chung et al., 2010). The conclusion of the Authors was that patients with bipolar disorder 
probably have purinergic dysfunction and evolve into gout thereafter.  
Finally, even in the absence of a psychiatric diagnosis, individuals with higher uric acid levels are more likely 
to show higher drive and disinhibition, suggesting that externalized traits of temperament are associated with higher 
serum uric acid levels (Lorenzi et al., 2010). A second study suggested that higher uric acid is associated with 
impulsivity in both humans (two longitudinal nonclinical community samples - total n= 6883) and mice (Sutin et al., 
2014).  
Some evidence exists, in conclusion, suggesting the possible involvement of purinergic dysfunctions in the 
pathophysiology of bipolar disorder and mania in particular. However, controversies also exist: two negative studies 
failed to show a benefit of adding allopurinol in mania (Fan et al., 2012; Weiser et al., 2014); Salvadore and colleagues 
(2010) failed to confirm a correlation between serum uric acid levels and YMRS scores in manic subjects.   
The aim of the present study is to compare serum uric acid levels in a large group of bipolar disorder patients 
during different phases of illness (mania, euthymia and bipolar depression) versus a control group made of patients with 
different psychiatric disorders. Based on previous literature, we made the following predictions: 1) serum uric acid 
levels will be significantly increased in bipolar patients as compared to controls; 2) serum uric acid levels will be 
significantly higher only in bipolar patients during mania and not during depression or euthymia; 3) serum uric acid 





Participants for this case-control cross-sectional study were 150 patients with Bipolar Disorder and 150 
controls made of age and gender-matched subjects with other Axis I Disorders.  
Bipolar patients were male or female subjects who met DSM-IV-TR criteria for a diagnosis of Bipolar 
Disorder I or II. Controls met DSM-IV-TR criteria for Major Depressive Disorder- MDD, Obsessive-Compulsive 
Disorder- OCD, and Schizophrenia. All subjects included were inpatients and outpatients consecutively referred to the 
Department of Neuroscience, Psychiatric Unit of the University of Turin (Italy); they were at least 18 years of age and 
were willing to voluntarily participate in the study. They were selected from September 2011 to October 2013. The 
aims of the study as well as study procedures were thoroughly explained to potential participants who gave written 
consent before participation. The study design was reviewed and approved by the local ethics committee. 
To be enrolled into this study, patients had to have a primary diagnosis of Bipolar Disorder I or II (DSM-IV-
TR, SCID-I). To be enrolled in the control group, patients had to have an Axis I diagnosis other than bipolar disorder 
(DSM-IV-TR, SCID-I) and they had to have never been exposed to mood stabilizers in their life. We included in the 
present study controls with Major Depressive Disorder only if in euthymic state for at least two months because it was 
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found that patients during major depressive episodes have lower serum uric acid levels (Wen et al., 2012). Subjects with 
severe or unstable medical illnesses were excluded from the study; patients with gout, chronic inflammatory disease, 
diabetes, renal failure or serum creatinine value >1.5 mg/dL, or other diseases associated with hyperuricemia were also 
excluded. Exclusion criteria were treatment with medications such as acetylsalicylic acic, allopurinol, thiazide diuretics, 
steroids, ibuprofen, vitamin E, and other drugs that could affect serum uric acid levels significantly. 
 
Assessments and procedures 
Data were obtained from each subject by a semi-structured interview with a format that covered the following 
areas: a) socio-demographic data (age, gender, marital status, years of education and occupational status); b) diagnosis: 
diagnoses (current and lifetime) were performed by clinicians with at least four years of postgraduate clinical 
experience by means of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I); c) clinical data (type 
of BD, age at onset of first affective episode, total number of affective episodes, duration of illness). Severity of mania 
was assessed using the Young Mania Rating Scale (YMRS) (Young et al, 1978) and severity of depression using the 
17-item Hamilton Depression Rating Scale (HAM-D) (Hamilton, 1960).	   
Lifetime and current medical conditions and use of medications at the time of interview were assessed; 
moreover, lifetime exposure to mood stabilizers was recorded by means of direct interview, family members’ interview 
(when available) and medical records review. Particular attention was devoted to lifetime exposure to lithium, valproate 
and carbamazepine because of the known potential effects of mood stabilizers on serum uric acid levels; in particular, 
lithium was found to lower uric acid plasma levels and to have uricosuric effects in mania (Anumonye et al., 1968); 
carbamazepine similarly decreased uric acid levels; in contrast, valproate appeared to have the opposite effect (Ring et 
al., 1991). 
A blood draw for routine blood exam was performed at hospital admission for inpatients, as part of the clinical 
management routine. For outpatients, patients were scheduled for a blood test within a week from the study visit. At the 
time when blood was drawn, patients were fasting for the previous 10 hours; patients who were not fasting were 
rescheduled. Blood exams included complete blood count, uric acid, creatinine, urea, sodium and potassium, thyroid 
hormone, AST, ALT, GGT, lithium, carbamazepine and valproate serum levels (for those on classic mood stabilizers). 
Blood samples were drawn in our clinic and examined in the “Baldi e Riberi” laboratory of analysis, San Giovanni 
Battista Hospital, Turin, Italy. Hyperuricaemia was defined by uric acid levels higher than 5.7 mg/dL, according to our 
laboratory reference range. 
With regards to the potential effects of mood stabilizers on uric acid levels, in order to help to tease apart the 
effects of chronicity of illness or treatment on uric acid levels we selected respectively, in primis, from the manic group 
thirteen drug-naïve patients during their first ever manic episode; secondly, a group of bipolar patients that had never 
received mood stabilizers. 
 
Statistical analysis 
Statistical analysis was performed using SPSS 20.0.0 (SPSS Inc., Chicago, IL, USA). For the comparisons of 
variables between cases and controls (matched subjects) we used the paired t-test and the McNemar’s test: continuous 
variables were compared using the paired t-test, categorical variables using the McNemar’s test. When considering 
non matched groups, we used the Student’s t-test and the Pearson’s Chi-square test, respectively, for continuous and 
dichotomous variables. Group comparisons used ANOVAs for continuous measures. After the use of ANOVA, we 
performed a Bonferroni’s post-hoc analysis in order to determine in which groups the significant differences were 
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found. Results were considered significant at p<0.05, two-tailed. Lastly, bivariate Pearson correlations were used to 
assess the relationship between serum uric acid levels and severity of manic symptoms as assessed using the YMRS 




Three hundred patients were enrolled: 150 bipolar patients and 150 age and gender-matched controls. Table 1 
shows socio-demographic and clinical characteristics of bipolar patients included. We could enroll 75 patients during a 
major depressive episode, 46 patients during a hypomanic or manic episode, and 29 patients in stable euthymia (at least 
2 months with HAM-D<6 and YMRS<8). Among bipolars, we could identify 84 patients who had never been exposed 
to mood stabilizers (which could affect serum uric acid levels), and 13 subjects with their first ever manic/hypomanic 
episode and who had not been previously exposed to mood stabilizers. 
The control group consisted of 46 (30.7%) patients with Obsessive-Compulsive Disorder (OCD), 95 (63.3%) 
with Major Depressive Disorder (MDD) (in euthymic state for at least two months) and 9 (6%) with Schizophrenia.  
Mean serum uric acid levels and rates of hyperuricaemia were both higher in the bipolar group than in the 
control group (Table 2). Serum uric acid levels and rates of hyperuricaemia of bipolar patients never exposed to mood 
stabilizers (lithium, valproic acid, carbamazepine)(N=84) were also higher than controls (Table 3). With regard to 
bipolars previously exposed to mood stabilizers (N=66), no differences were detected (mean uric acid levels: 5.08±1.43 
in never exposed vs 5.03±1.49 mg/dL in previously exposed; t=-.210, p=.834). Patients taking lithium (N=59) also did 
not differ from those not taking it (N=91)(mean uric acid levels: 5.09±1.51 vs 5.04±1.43 mg/dL; t=-.226, p=.821). 
There were no statistically significant differences of serum uric acid levels between bipolar patients during 
different phases of illness, whereas uric acid levels in each phase were significantly higher than those of the control 
group (Figure 1). When we selected drug-naïve bipolar patients during their first-ever (hypo)manic episode (First 
Episode, Drug-Naïve FEDN) we found their mean serum uric acid levels higher than those of all bipolar patients 
(except FEDN) and all manic patients (except FEDN)(Figure 2). When we excluded FEDN patients from the bipolar 
group, serum uric acid levels of all bipolars and manic bipolars were still significantly higher than controls (respectively 
4.93±1.36 vs. 4.17±1.05; t=-5.326, p<.001 and 4.60±1.59 vs 4.17±1.05; t=-5.910, p<.001). There were no statistically 
significant differences between Bipolar I and II; bipolar II patients showed higher serum uric acid levels than MDD and 
OCD patients, whereas bipolar I subjects only differed from MDD patients (Figure 3); schizophrenia subjects (N=9 – 
data not shown in figure 3) showed the lower mean uric acid levels (4.07±0.67).  
Uric acid levels were not correlated with manic episode severity as assessed using the YMRS in neither all 
bipolars together (Pearson correlation r=.043; p=.604) nor patients in hypomania/mania only (Pearson correlation 
r=.158; p=.295). In bipolar depressed patients uric acid levels were not correlated with HAM-D total scores (Pearson 




Results of our study support a role of purinergic system dysfunctions in the pathophysiology of bipolar 
disorder and are in line with results of different studies which investigated not only serum uric acid levels in bipolars 
(De Berardis et al., 2008; Salvadore et al., 2010; Kesebir et al., 2014), but also the efficacy and tolerability of the 
purinergic modulator allopurinol as an add-on treatment in bipolar mania (Akhondzadeh et al., 2006; Machado-Vieira et 
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al., 2008; Jahangard et al., 2014). We measured serum uric acid levels because peripheral and central uric acid levels 
have a strong positive association (Bowman et al., 2010); we then assume that differences in serum uric acid levels 
found in our study reflect differences in central uric acid levels. 
According to our predictions, we found that serum uric acid levels are significantly increased in bipolar 
patients as compared a control group made of patients with different psychiatric disorders, such as Major Depressive 
Disorder, Obsessive-Compulsive Disorder, and Schizophrenia (only 9 subjects). As gender-based differences in 
oxidative stress parameters have been found (women seem more susceptible to oxidative stress than male and have 
higher serum uric acid levels)(Wiener et al., 2014), control subjects were matched to patients by gender. Moreover, as 
age might increase the rate of hyperuricaemia we also matched our controls by age of bipolars. Increased levels of uric 
acid mean accelerated purinergic transformation and decreased adenosinergic transmission (Burnstock, 2008). As 
adenosinergic receptors (mostly A1 receptors) limit cellular excitability by inhibiting neurotransmitter release in the 
central nervous system, the increase in serum uric acid levels found in bipolars as compared to other psychiatric 
disorders might account for the vulnerability of bipolars to the development of recurrences (trait vulnerability marker: 
the nervous system of bipolars is more vulnerable to develop affective episodes in response to stress because of a 
purinergic dysfunction – mania as a kindling-like behavioral manifestation of purinergic dysfunction) or might only 
imply that once a manic episode starts, the purinergic dysfunction results from mania and contributes to the 
maintenance of manic symptoms (state marker of mania).   
Uric acid levels were also significantly different between bipolar I and II patients and those with unipolar 
MDD, extending in a larger sample what recently found by Kesebir et al. (2014) in a group of 41 bipolars and 30 MDD 
subjects: they found that uric acid levels of BD patients were higher than both patients with recurrent MDD and healthy 
controls. Additionally, they also found that uric acid levels of MDD patients were lower than healthy subjects. Another 
study found uric acid levels significantly reduced in MDD patients compared to controls (Wen et al., 2012), suggesting 
that purinergic dysfunctions might affect the whole spectrum of affective disorders. 
Whether purinergic dysfunctions as shown by an increase in serum uric acid levels are a state marker of mania 
or a trait marker of bipolar disorder still remains unanswered: contrary to our prediction, based on results of the study 
by De Berardis and colleagues (2008), we failed to detect differences between bipolar patients in (hypo)mania, major 
depressive episode and stable euthymia (at least two months). We also failed to detect a correlation between uric acid 
levels and severity of mania as from YMRS scores, both in manic patients only and in the whole group of bipolars 
(Salvadore et al., 2010 also failed to find this correlation). However, we enrolled a group of relatively severe bipolar 
patients, as evidenced by the long duration of illness (mean 19.95±13.05 years from onset of first affective episode and 
enrolment in the study) and the high number of lifetime affective episodes (mean 6.9±4.12). A possible explanation of 
the failure to detect an effect of the current (hypo)manic state on uric acid levels is then that patients in depression 
(bipolar depression) and euthymia might still present higher serum uric acid levels because of recent (maybe too recent) 
episodes of (hypo)mania.  
An alternative explanation is that uric acid levels are a trait marker of bipolar disorder rather than a state 
marker of mania. This hypothesis is supported by results of two studies performed by the same research group (Kesebir 
et al., 2013; Kesebir et al., 2014). In the first study they also failed to find a significant difference in uric acid levels 
between manic, depressive and euthymic bipolars, while all three groups differed from healthy subjects (increased 
levels as compared to healthy subjects)(Kesebir et al., 2013); in a recent study they included only bipolars in remission, 
and still found a significant increase in serum uric acid levels as compared to controls (Kesebir et al., 2014). Rather than 
a state marker, uric acid levels may be then viewed as a trait marker of a continual predisposition for bipolar disorder. 
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A third possible explanation for our failure to detect differences among bipolars is that patients (manic patients 
as well as all bipolars) have been exposed to mood stabilizers such as lithium, valproate or carbamazepine, among 
others, that alter uric acid levels. We then performed a separate analysis on a small group of manic patients who were 
drug-naïve at measurements, had never been exposed to mood stabilizers, and had their first-ever affective episode 
(FEDN=First Episode, Drug-Naïve); this group consisted of only 13 patients. Uric acid levels were significantly higher 
(6.41 mg/dL) in this group as compared to both all bipolars (except FEDN), and all manic patients (except FEDN). This 
result, to our opinion, supports the hypothesis that uric acid levels are particularly higher in first manic episodes not yet 
treated with mood stabilizers and is in agreement with results of Salvadore and colleagues (2010).   
The investigation of serum uric acid levels as a screening test in mania, as proposed by Machado-Vieira 
(2012), may help to identify earlier those bipolar patients who will respond better to treatments, including the addition 
to mood stabilizers of allopurinol. It may be speculated, from results of our study, that the addition of allopurinol would 
be particularly effective in first episode manic patients. Routine monitoring of serum uric acid levels might be then 
useful in individualizing treatments and monitoring clinical outcome.  
Our study has some limitations; first, our study lacks a control group made of healthy subjects. Second, the 
choice of a control group of patients with mainly OCD or MDD in remission was made for practical reasons, and limits 
our ability to examine the specificity of the purinergic dysfunction with regard to other psychiatric conditions. A third 
limitation is that we could not completely control for the exposure to mood stabilizers or antipsychotics in the bipolar 
group; however, we identified a large subgroup of subjects (N=84) who had never been exposed before to lithium, 
carbamazepine (both drugs seem to decrease uric levels – Anumonye et al., 1968), or valproate (which does not reduce 
uric levels but might increase them – Ring et al., 1991) and this subgroup also showed increased uric acid levels as 
compared to controls. It is important to note that the effect of mood stabilizers (and mostly of antipsychotics used for 
the treatment of bipolar disorder) on uric acid levels in relationship to clinical improvement has not been systematically 
evaluated. With this regard, longitudinal studies with multiple measurements of serum uric acid levels at different 
stages of illness in the same patient are strongly needed in order to clarify both the state or trait value of the increase in 
uric acid levels and the effect of treatments. Other limitations of our study consist in the fact that we did not adjust our 
results for BMI, or the presence of metabolic syndrome or its components; association between bipolar disorder and 
hyperuricemia does not mean causation, and hyperuricemia could be linked to metabolic syndrome (which is highly 
prevalent among bipolar subjects)(Salvi et al., 2008) or its component. 
In conclusion, our study provides further evidence of a purinergic dysfunction associated with bipolar disorder; 
the notion that the purinergic system might be involved in bipolar disorder dates back to Kraepelin, who was the first to 
report an association between mania, uric acid excretion, hyperuricaemia and gout (Kraepelin, 1921). Since then, 
several studies provided support to the hypothesis of purinergic dysfunctions, both by measuring serum uric acid levels 
(De Berardis et al., 2008; Salvadore et al., 2010; Kesebir et al., 2014) and by effectively treating manic patients with 
allopurinol as add-on (Akhondzadeh et al., 2006; Machado-Vieira et al., 2008; Jahangard et al., 2014). The role of uric 
acid, adenosine and the whole purinergic system in the pathophysiology not only of bipolar disorder but also of 
affective temperaments (as suggested by Kesebir et al. 2014) and major depression needs to be further elucidated. It is 
possible that increased uric acid levels are both a trait marker of higher vulnerability to impulsivity, hyperthymic and 
irritable temperaments (as suggested by Lorenzi et al., 2010; and Sutin et al., 2014) and frank bipolar disorder, and are 
even more increased during mania (mostly in the first manic episode of drug-naïve patients). 
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Table 1. Socio-demographic and clinical characteristics of bipolar patients included 
 Patients (N=150) 
Actual age (years) (Mean±SD) 47.74±15.48 
Gender (males), N (%) 63 (42.0) 
Educational level (years) (Mean±SD) 12.65±4.42 










Currently working, N (%) 79 (52.7) 






Age at onset (years) (Mean±SD) 27.93±10.76 
Total number of episodes (Mean±SD) 6.9±4.12 
Duration of illness (years) (Mean±SD) 19.95±13.05 
Actual Episode, N (%) 
MDE  
Manic/hypomanic Episode  





YMRS, all patients (N=46) with manic/hypomanic episode (Mean±SD) 19.37±6.57 




HAM-D, all patients (N=74) with MDE (Mean±SD) 16.11±5.20 
















BMI (Mean±SD) 25.36±4.58 
 
BMI: Body Mass Index 
YMRS: Young Mania Rating Scale 
HAM-D: Hamilton Depression Rating Scale  
HAM-A: Hamilton Anxiety Rating Scale 
MDE: Major Depressive Episode 
 
	   12	  
Table 2. Mean serum uric acid levels and rates of hyperuricaemia (bipolar patients vs. controls; paired t-test and 
McNemar test) 





Uric Acid (mg/dL) (Mean±SD) 
Normal Range: 2.4-5.7 mg/dL 
5.06±1.45 4.17±1.05 6.711 <.001 
Hyperuricaemia (Uric Acid>5.7 mg/dL), N (%) 46 (30.7) 10 (6.7) 28.454 <.001 
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Table 3. Mean serum uric acid levels and rates of hyperuricaemia (bipolar patients never exposed to mood stabilizers 
vs. controls) 





Actual age (years) (Mean±SD) 46.31±15.49 47.99±15.95 .780 .436 
Gender (males), N (%) 41 (48.8) 63 (42.0) 1.011 .315 
Uric Acid (mg/dL), (Mean±SD) 
Normal Range: 2.4-5.7 mg/dL 
5.08±1.43 4.17±1.05 -5.578 <.001 
Hyperuricaemia (Uric Acid>5.7 mg/dL), N (%) 25 (29.8) 10 (6.7) 22.579 <.001 
	  
	  
 
 
